Literature DB >> 27236869

Meeting of the Strategic Advisory Group of Experts on immunization, April 2016 – conclusions and recommendations.

.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27236869

Source DB:  PubMed          Journal:  Wkly Epidemiol Rec        ISSN： 0049-8114


× No keyword cloud information.
  30 in total

Review 1.  Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? There Is Only One True Winner.

Authors:  Scott B Halstead
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

2.  Evaluation of the impact of Shandong illegal vaccine sales incident on immunizations in China.

Authors:  Lei Cao; Jingshan Zheng; Lingsheng Cao; Jian Cui; Qiyou Xiao
Journal:  Hum Vaccin Immunother       Date:  2018-06-19       Impact factor: 3.452

3.  Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial.

Authors:  Cynthia J Snider; Khalequ Zaman; Concepcion F Estivariz; Mohammad Yunus; William C Weldon; Kathleen A Wannemuehler; M Steven Oberste; Mark A Pallansch; Steven Gf Wassilak; Tajul Islam A Bari; Abhijeet Anand
Journal:  Lancet       Date:  2019-05-16       Impact factor: 79.321

4.  Dengue hospitalisations in Brazil: annual wave from West to East and recent increase among children.

Authors:  J Wunderlich; R Acuña-Soto; W J Alonso
Journal:  Epidemiol Infect       Date:  2017-12-13       Impact factor: 4.434

5.  A Cluster-Randomized Controlled Trial to Reduce Diarrheal Disease and Dengue Entomological Risk Factors in Rural Primary Schools in Colombia.

Authors:  Hans J Overgaard; Neal Alexander; Maria Ines Matiz; Juan Felipe Jaramillo; Victor Alberto Olano; Sandra Vargas; Diana Sarmiento; Audrey Lenhart; Thor Axel Stenström
Journal:  PLoS Negl Trop Dis       Date:  2016-11-07

6.  The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study.

Authors:  Stefan Flasche; Mark Jit; Isabel Rodríguez-Barraquer; Laurent Coudeville; Mario Recker; Katia Koelle; George Milne; Thomas J Hladish; T Alex Perkins; Derek A T Cummings; Ilaria Dorigatti; Daniel J Laydon; Guido España; Joel Kelso; Ira Longini; Jose Lourenco; Carl A B Pearson; Robert C Reiner; Luis Mier-Y-Terán-Romero; Kirsten Vannice; Neil Ferguson
Journal:  PLoS Med       Date:  2016-11-29       Impact factor: 11.069

7.  The Dengue Vaccine Dilemma: Balancing the Individual and Population Risks and Benefits.

Authors:  Jacqueline Deen
Journal:  PLoS Med       Date:  2016-11-29       Impact factor: 11.069

8.  Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy.

Authors:  Maia A Rabaa; Yves Girerd-Chambaz; Kien Duong Thi Hue; Trung Vu Tuan; Bridget Wills; Matthew Bonaparte; Diane van der Vliet; Edith Langevin; Margarita Cortes; Betzana Zambrano; Corinne Dunod; Anh Wartel-Tram; Nicholas Jackson; Cameron P Simmons
Journal:  Elife       Date:  2017-09-05       Impact factor: 8.140

9.  Implementing revised RED approaches to immunize in an evolving African landscape.

Authors:  Craig Alexander Burgess
Journal:  Pan Afr Med J       Date:  2017-06-21

10.  Fractional-Dose Inactivated Poliovirus Vaccine Campaign - Sindh Province, Pakistan, 2016.

Authors:  Aslam Pervaiz; Chukwuma Mbaeyi; Mirza Amir Baig; Ashley Burman; Jamal A Ahmed; Sharifa Akter; Fayaz A Jatoi; Abdirahman Mahamud; Rana Jawad Asghar; Naila Azam; Muhammad Nadeem Shah; Mumtaz Ali Laghari; Kamaluddin Soomro; Mufti Zubair Wadood; Derek Ehrhardt; Rana M Safdar; Noha Farag
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-12-01       Impact factor: 17.586
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.